Discovering mechanisms of resistance to capivasertib (Truqap):
A direct-to-patient liquid biopsy study
About The Study
We are a team of breast cancer doctors and researchers seeking to discover new resistance mechanisms to breast cancer therapies. In this direct-to-patient study, we will collect liquid biopsies from patients before and after treatment with the AKT inhibitor capivasertib (Truqap) and use next generation sequencing by Caris Life Sciences to uncover new molecular changes that occur on treatment. We invite patients from all locations to join us in this effort to better deliver and tailor breast cancer treatments in the future.
Study Information
1
Who is eligible for this study?
-
Age 18 or older
-
Diagnosed with hormone receptor-positive, HER2 negative advanced breast cancer
-
Planned to start capivasertib (Truqap) as next line of therapy
-
Willing to undergo two research blood draws and mail these samples out for genetic testing
2
What does the study entail?
-
Undergoing one blood draw (performed at any location of your choice) prior to starting capivasertib
-
Undergoing a second blood draw after stopping capivasertib
-
The study team will communicate with your oncologist's office for medical updates every 3 months while you are on the study
3
What are the next steps if I am interested?
-
Provide us your email and we will be in touch with more information and next steps!
-
We will mail you all the required study materials and stay in touch with you virtually
Why join this study?
Research
We will partner with Caris Life Sciences to perform next generation sequencing to discover the molecular changes that occur in response to breast cancer therapies. We will start by focusing on the AKT inhibitor capivasertib (Truqap).
Flexibility
The study will be conducted remotely, and participants will not be required to travel to a study site. We will mail all study materials to your house and communicate with you virtually.
Outreach
We aim to recruit patients from all locations and backgrounds to join this effort, so that our results will be applicable to breast cancer patients at large.
Our Team
We are a team of breast cancer doctors and researchers based out of Columbia University Irving Medical Center.
Get in Touch
If you are interested in this study, please share your contact information using this form, and the study team will get in touch with you with further details.